Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QLC5508 and/or QLH12016 in combination with other antitumor therapies for advanced prostate cancer
CTR20253721Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C, QLH12016 in prostate cancer (PCa), sponsored by Qilu Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
MHB088CQLH12016
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20253721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253721.